Acquired dysfibrinogenaemia in acute and chronic liver disease. 1977

D A Lane, and M F Scully, and D P Thomas, and V V Kakkar, and I L Woolf, and R Williams

Plasma from patients with both acute and chronic liver disease has been examined for evidence of acquired dysfibrinogenaemia, using electrophoretic methods and coagulation tests. An examination of isolated fibrins upon SDS polyacryamide gel electrophoresis failed to demonstrate any molecular or structural defect associated with the polypeptide chains of the patients' fibrinogen or fibrinogen derivatives produced by thrombin or plasmin. However, purified fibrin monomers isolated from plasma using both Reptilase and thrombin exhibited delayed polymerization rates and the occurrence of acquired dysfibrinogenaemia in liver disease is therefore confirmed.

UI MeSH Term Description Entries
D008107 Liver Diseases Pathological processes of the LIVER. Liver Dysfunction,Disease, Liver,Diseases, Liver,Dysfunction, Liver,Dysfunctions, Liver,Liver Disease,Liver Dysfunctions
D012103 Batroxobin A proteolytic enzyme obtained from the venom of fer-de-lance (BOTHROPS ATROX). It is used as a plasma clotting agent for fibrinogen and for the detection of fibrinogen degradation products. The presence of heparin does not interfere with the clotting test. Hemocoagulase is a mixture containing batroxobin and factor X activator. EC 3.4.21.-. Defibrol,Hemocoagulase,Defibrase,Reptilase,Reptilase-DEF,Reptilase DEF
D001778 Blood Coagulation Disorders Hemorrhagic and thrombotic disorders that occur as a consequence of abnormalities in blood coagulation due to a variety of factors such as COAGULATION PROTEIN DISORDERS; BLOOD PLATELET DISORDERS; BLOOD PROTEIN DISORDERS or nutritional conditions. Coagulation Disorders, Blood,Disorders, Blood Coagulation,Blood Coagulation Disorder,Coagulation Disorder, Blood,Disorder, Blood Coagulation
D001780 Blood Coagulation Tests Laboratory tests for evaluating the individual's clotting mechanism. Coagulation Tests, Blood,Tests, Blood Coagulation,Blood Coagulation Test,Coagulation Test, Blood,Test, Blood Coagulation
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D005337 Fibrin A protein derived from FIBRINOGEN in the presence of THROMBIN, which forms part of the blood clot. Antithrombin I
D005340 Fibrinogen Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products. Coagulation Factor I,Factor I,Blood Coagulation Factor I,gamma-Fibrinogen,Factor I, Coagulation,gamma Fibrinogen
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute
D000721 Ancrod An enzyme fraction from the venom of the Malayan pit viper, Agkistrodon rhodostoma. It catalyzes the hydrolysis of a number of amino acid esters and a limited proteolysis of fibrinogen. It is used clinically to produce controlled defibrination in patients requiring anticoagulant therapy. EC 3.4.21.-. Agkistrodon Serine Proteinase,Agkistrodon rhodostoma Venom Protease,Arvin,Arvin IRC-50,Arwin,Venacil,Arvin IRC 50,Arvin IRC50

Related Publications

D A Lane, and M F Scully, and D P Thomas, and V V Kakkar, and I L Woolf, and R Williams
June 1982, Journal of clinical pathology,
D A Lane, and M F Scully, and D P Thomas, and V V Kakkar, and I L Woolf, and R Williams
January 1980, Thrombosis research,
D A Lane, and M F Scully, and D P Thomas, and V V Kakkar, and I L Woolf, and R Williams
April 1983, Medical laboratory sciences,
D A Lane, and M F Scully, and D P Thomas, and V V Kakkar, and I L Woolf, and R Williams
June 1988, Journal of clinical pathology,
D A Lane, and M F Scully, and D P Thomas, and V V Kakkar, and I L Woolf, and R Williams
January 1978, Journal of clinical pathology,
D A Lane, and M F Scully, and D P Thomas, and V V Kakkar, and I L Woolf, and R Williams
January 1982, Haemostasis,
D A Lane, and M F Scully, and D P Thomas, and V V Kakkar, and I L Woolf, and R Williams
May 1984, Thrombosis research,
D A Lane, and M F Scully, and D P Thomas, and V V Kakkar, and I L Woolf, and R Williams
April 2007, Lancet (London, England),
D A Lane, and M F Scully, and D P Thomas, and V V Kakkar, and I L Woolf, and R Williams
January 1976, Sangre,
D A Lane, and M F Scully, and D P Thomas, and V V Kakkar, and I L Woolf, and R Williams
August 2019, Revue medicale suisse,
Copied contents to your clipboard!